544 related articles for article (PubMed ID: 22290256)
21. Glioblastoma multiforme: a review of where we have been and where we are going.
Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer management: opportunities and barriers to an individualized approach.
Perez EA
Oncologist; 2011; 16 Suppl 1():20-2. PubMed ID: 21278437
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.
Bex A; Gore M; Mulders P; Sternberg CN
BJU Int; 2012 Nov; 110(9):1289-300. PubMed ID: 22624610
[TBL] [Abstract][Full Text] [Related]
24. Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Stupp R; Hegi ME; van den Bent MJ; Mason WP; Weller M; Mirimanoff RO; Cairncross JG; ;
Oncologist; 2006 Feb; 11(2):165-80. PubMed ID: 16476837
[TBL] [Abstract][Full Text] [Related]
25. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
26. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
27. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
28. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
30. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.
Florio T; Barbieri F
Drug Discov Today; 2012 Oct; 17(19-20):1103-10. PubMed ID: 22704957
[TBL] [Abstract][Full Text] [Related]
31. SnapShot: glioblastoma multiforme.
Kotliarova S; Fine HA
Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
[No Abstract] [Full Text] [Related]
32. The role of integrins in glioma biology and anti-glioma therapies.
Tabatabai G; Tonn JC; Stupp R; Weller M
Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
[TBL] [Abstract][Full Text] [Related]
33. Treatment of elderly patients with glioblastoma: from clinical evidence to molecular highlights.
Chargari C; Feuvret L; Bauduceau O; Ricard D; Cuenca X; Delattre JY; Mazeron JJ
Cancer Treat Rev; 2012 Dec; 38(8):988-95. PubMed ID: 22289687
[TBL] [Abstract][Full Text] [Related]
34. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic options in recurrent glioblastoma--An update.
Seystahl K; Wick W; Weller M
Crit Rev Oncol Hematol; 2016 Mar; 99():389-408. PubMed ID: 26830009
[TBL] [Abstract][Full Text] [Related]
36. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
37. Glioblastoma: molecular analysis and clinical implications.
Huse JT; Holland E; DeAngelis LM
Annu Rev Med; 2013; 64():59-70. PubMed ID: 23043492
[TBL] [Abstract][Full Text] [Related]
38. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
[TBL] [Abstract][Full Text] [Related]
39. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
Bastien JI; McNeill KA; Fine HA
Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]